Congestive heart failure (CHF) is a leading health burden for which there is an unmet need for understanding disease progression in order to develop therapeutic, diagnostic and preventative strategies. Increasing evidence has demonstrated that the kidney as well as the heart plays a central role in CHF. The objective of this highly translational application is to define mechanisms of an impaired link between the heart and kidney in the control of cardiorenal homeostasis in human and experimental CHF and to promote novel therapeutics and innovative diagnostics for cardiorenal protection. Our broad working hypothesis is that a defect in the GC/cGMP pathway which links the heart and kidney is a key mechanism of impaired renal and cardiac function in CHF. We also hypothesize that cardiorenal dysfunction can be overcome with innovative GC/cGMP-based therapeutics and that knowledge gained will also lead to novel diagnostics for CHF.
Aim 1 : Establish that proBNP is a circulating hormone secreted by the normal human heart that is processed to mature BNP in the circulation. Establish that the processing of circulating proBNP by corin is impaired in CHF.
Aim 2 : Establish that proBNP is the superior molecular form of BNP to serve as a biomarker for the detection of ventricular dysfunction and as a prognostic biomarker for adverse cardiovascular outcomes. Establish that the BNP genetic variant rs198389 affects circulating proBNP in the general community and that the optimal BNP-based biomarker strategy integrates measurement of proBNP with genotyping for rs198389.
Aim 3 : Establish that dual GC-A/GC-B activation with a Mayo designed chimeric NP (CD-NP) is superior to GC-A activation alone with BNP in improving cardiorenal function in humans with CHF and impaired renal function. Establish the comprehensive cGMP activating properties of dual GC-A/GC-B stimulation with CD-NP as compared to GC-A alone with BNP and GC-B alone with CNP in human renal glomerular cells. Finally, establish that CD-NP is highly resistant to protease degradation by human NEP secondary to the presence of the C-terminus of DNP.
Aim 4 : Establish that CHF progression can be delayed with chronic GC-A/GC-B activation with CD-NP compared to GC-A activation with BNP alone in a model of progressive CHF.

Public Health Relevance

A family of hormones in the heart and kidney link these two organs that contribute to the optimal regulation of fluid volume and blood pressure. In response to stress to the heart these hormones function to preserve heart and kidney function but when heart failure is severe this system may be defective. Our proposal seeks to better understand this hormonal heart and kidney connection leading to novel new drugs and diagnostics for human heart failure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL036634-26
Application #
8467737
Study Section
Special Emphasis Panel (ZRG1-CVRS-C (02))
Program Officer
Shah, Monica R
Project Start
1990-04-01
Project End
2015-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
26
Fiscal Year
2013
Total Cost
$371,573
Indirect Cost
$135,953
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Buglioni, Alessia; Burnett Jr, John C (2015) Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta 443:8-Mar
Huntley, Brenda K; Sandberg, Sharon M; Heublein, Denise M et al. (2015) Pro-B-type natriuretic peptide-1-108 processing and degradation in human heart failure. Circ Heart Fail 8:89-97
McKie, Paul M; AbouEzzeddine, Omar F; Scott, Christopher G et al. (2014) High-sensitivity troponin I and amino-terminal pro--B-type natriuretic peptide predict heart failure and mortality in the general population. Clin Chem 60:1225-33
Pereira, Naveen L; Redfield, Margaret M; Scott, Christopher et al. (2014) A functional genetic variant (N521D) in natriuretic peptide receptor 3 is associated with diastolic dysfunction: the prevalence of asymptomatic ventricular dysfunction study. PLoS One 9:e85708
Volpe, Massimo; Rubattu, Speranza; Burnett Jr, John (2014) Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J 35:419-25
McKie, Paul M; Cataliotti, Alessandro; Ichiki, Tomoko et al. (2014) M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics. J Am Heart Assoc 3:e000206
Ichiki, Tomoko; Schirger, John A; Huntley, Brenda K et al. (2014) Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications. J Mol Cell Cardiol 75:199-205
von Lueder, Thomas G; Sangaralingham, S Jeson; Wang, Bing H et al. (2013) Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail 6:594-605
Mangiafico, Sarah; Costello-Boerrigter, Lisa C; Andersen, Ingrid A et al. (2013) Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 34:886-893c
Ichiki, Tomoko; Boerrigter, Guido; Huntley, Brenda K et al. (2013) Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis. Am J Physiol Regul Integr Comp Physiol 304:R102-9

Showing the most recent 10 out of 219 publications